364 related articles for article (PubMed ID: 30767164)
1. Cabozantinib: A Review in Advanced Hepatocellular Carcinoma.
Deeks ED
Target Oncol; 2019 Feb; 14(1):107-113. PubMed ID: 30767164
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib: An evolving therapy for hepatocellular carcinoma.
El-Khoueiry AB; Hanna DL; Llovet J; Kelley RK
Cancer Treat Rev; 2021 Jul; 98():102221. PubMed ID: 34029957
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives.
Trojan J
Drugs; 2020 Aug; 80(12):1203-1210. PubMed ID: 32671719
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma.
Nguyen L; Chapel S; Tran BD; Lacy S
J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):577-589. PubMed ID: 31637577
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Abou-Alfa GK; Meyer T; Cheng AL; El-Khoueiry AB; Rimassa L; Ryoo BY; Cicin I; Merle P; Chen Y; Park JW; Blanc JF; Bolondi L; Klümpen HJ; Chan SL; Zagonel V; Pressiani T; Ryu MH; Venook AP; Hessel C; Borgman-Hagey AE; Schwab G; Kelley RK
N Engl J Med; 2018 Jul; 379(1):54-63. PubMed ID: 29972759
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib.
Personeni N; Pressiani T; Rimassa L
Future Oncol; 2019 Jul; 15(21):2449-2462. PubMed ID: 31204849
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma.
Liao W; Huang J; Hutton D; Zhu G; Wu Q; Wen F; Bai L; Li Q
Liver Int; 2019 Dec; 39(12):2408-2416. PubMed ID: 31544330
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
Casadei-Gardini A; Rimassa L; Rimini M; Yoo C; Ryoo BY; Lonardi S; Masi G; Kim HD; Vivaldi C; Ryu MH; Rizzato MD; Salani F; Bang Y; Pellino A; Catanese S; Burgio V; Cascinu S; Cucchetti A
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3665-3671. PubMed ID: 33745079
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib for the treatment of hepatocellular carcinoma.
Personeni N; Rimassa L; Pressiani T; Smiroldo V; Santoro A
Expert Rev Anticancer Ther; 2019 Oct; 19(10):847-855. PubMed ID: 31603008
[No Abstract] [Full Text] [Related]
12. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
Kelley RK; Verslype C; Cohn AL; Yang TS; Su WC; Burris H; Braiteh F; Vogelzang N; Spira A; Foster P; Lee Y; Van Cutsem E
Ann Oncol; 2017 Mar; 28(3):528-534. PubMed ID: 28426123
[TBL] [Abstract][Full Text] [Related]
13. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.
Kelley RK; Ryoo BY; Merle P; Park JW; Bolondi L; Chan SL; Lim HY; Baron AD; Parnis F; Knox J; Cattan S; Yau T; Lougheed JC; Milwee S; El-Khoueiry AB; Cheng AL; Meyer T; Abou-Alfa GK
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32847838
[TBL] [Abstract][Full Text] [Related]
14. Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States.
Sieg M; Hartmann M; Settmacher U; Arefian H
BMC Gastroenterol; 2020 Apr; 20(1):120. PubMed ID: 32316925
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
Trojan J; Mollon P; Daniele B; Marteau F; Martín L; Li Y; Xu Q; Piscaglia F; Zaucha R; Sarker D; Lim HY; Venerito M
Adv Ther; 2021 May; 38(5):2472-2490. PubMed ID: 33822328
[TBL] [Abstract][Full Text] [Related]
16. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib: A Review in Advanced Renal Cell Carcinoma.
Al-Salama ZT; Keating GM
Drugs; 2016 Dec; 76(18):1771-1778. PubMed ID: 27909994
[TBL] [Abstract][Full Text] [Related]
18. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
da Fonseca LG; Reig M; Bruix J
Clin Liver Dis; 2020 Nov; 24(4):719-737. PubMed ID: 33012455
[TBL] [Abstract][Full Text] [Related]
20. Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma.
Schwartz G; Darling JO; Mindo M; Damicis L
Target Oncol; 2020 Aug; 15(4):549-565. PubMed ID: 32770441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
